Cancer treatment just got faster: FDA approves Genentech’s Tecentriq Hybreza for quick 7-minute injection

The U.S. Food and Drug Administration (FDA) has granted approval for Tecentriq Hybreza, the first and only PD-(L)1 inhibitor for subcutaneous injection, developed by Genentech, ... Read More